Health Canada Extends Evkeeza Approval to Treat HoFH in Infants

Health Canada extends Evkeeza approval to treat HoFH in infants

Health Canada Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

TORONTO, July 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultra-rare genetic diseases, today announced that Health Canada has extended the approval of…

Health Canada extends Evkeeza approval for children with HoFH

Ultragenyx Pharmaceuticals has announced the extension of approval by Health Canada for Evkeeza (evinacumab) for HoFH.

Health Canada Approves Evkeeza® for Treating Homozygous Familial Hypercholesterolemia in Children 6 Months and Older

Health Canada has announced an important update in the treatment of homozygous familial hypercholesterolemia (HoFH), extending the approval of Evkeeza® (evinacumab) to include children as young as six months old. This development marks a significant advancement in managing the rare genetic disorder characterized by dangerously high cholesterol levels from an early age. The expanded authorization aims to provide younger patients with improved acc…